Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro- D-glucose (FDG) PET

Radiology

Volumn 203, Issue 2, 1997, Pages 323-327

  Adler, Lee P ^a   Faulhaber, Peter F ^a   Schnur, Kathryn C ^a   Al Kasi, Nadia L ^a,b   Shenk, Robert R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Breast neoplasms, emission CT (ECT); Breast neoplasms, staging; Fluorine; Lymphatic system, radionuclide studies

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS;

EID: 0030984978     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.203.2.9114082     Document Type: Article

References (29)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 65:5-27.
2. Bryan RM, Mercer RJ, Bennett RC, Rennie GC. Prognostic factors in breast cancer and the development of a prognostic index. Br J Surg 1986; 73:267-271.
3. Wilking N, Rutqvist LE, Carstensen J, Mattsson A, Skoog L. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncol 1992; 31:29-35.
4. Henderson IC, Harris JR, Kinne DW, Hellman S. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 3rd ed. Philadelphia, Pa: Lippincott, 1989; 1197-1268.
5. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA 1991; 265:391-395.
6. Danforth DN Jr. The role of axillary lymph node dissection in the management of breast cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 3rd ed. Philadelphia, Pa: Lippincott, 1992; 1-16.
7. Cady B. Dilemmas in breast disease. Breast J 1995; 2:121-124.
8. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312:674-681.
9. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
10. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216:27-34.
11. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
12. Pamilo M, Soiva M, Lavast EM. Real-time ultrasound, axillary mammography and clinical examination in the detection of axillary lymph node metastases in breast cancer patients. J Ultrasound Med 1989; 8:115-120.
13. March DE, Wechsler RJ, Kurtz AF, Rosenberg AL, Needleman L. CT-pathologic correlation of axillary lymph nodes in breast carcinoma. J Comput Assist Tomogr 1991; 15:440-444.
14. Bruneton JN, Caramella E, Hery M, Aubanel D, Manzino JJ, Picard JL. Axillary lymph node metastases in breast cancer: preoperative detection with US. Radiology 1986; 158:325-326.
15. Tjandra JJ, Sacks NPM, Thompson CH, et al. The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study. Br J Cancer 1989; 59:291-302.
16. Lamki LM, Buzdar AU, Singletary SE, et al. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase 1 study. J Nucl Med 1991; 32:1326-1332.
17. Taylor JL, Taylor DN, Lowry C, et al. Radioimmunoscintigraphy of metastatic breast carcinoma. Eur J Surg Oncol 1992; 18:57-63.
18. Waxman AD, Ramanna L, Memsic LD, et al. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 1993; 34:18-23.
19. Aktolun C, Bayhan K, Kir M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors: preliminary results and comparison with TI-201. Clin Nucl Med 1992; 17:171-176.
20. Khalkhali I, Cutrone JA, Mena IG, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196:421-426.
21. Villanueva-Meyer J, Leonard MH Jr, Briscoe E, et al. Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996; 37:926-930.
22. Maublant J, de Latour M, Mestas D, et al. Technetium-99m-sestamibi uptake in breast tumor and associated lymph nodes. J Nucl Med 1996; 37:922-925.
23. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988; 29: 1521-1525.
24. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765-770.
25. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649.
26. Carter CL, Allen C, Henson DE. Relation of rumor size, lymph node status and survival in 24,740 breast cancer patients. Cancer 1989; 63:181-187.
27. Swain S, Lippman M. Intra epithelial carcinoma of the breast: lobular carcinoma in situ and ductal carcinoma in situ. In: Lippman M, Litchter A, Danforth D, eds. Diagnosis and management of breast cancer. Philadelphia, Pa: Saunders, 1988; 296-325.
28. Balch CM, Singletary SE, Bland KI. Clinical decision-making in early breast cancer. Ann Surg 1992; 217:207-225.
29. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Cancer 1994; 73:664-667.